October 22, 2018 / 7:31 AM / a month ago

BRIEF-Novartis reports phase III success for melanoma cocktail

Oct 22 (Reuters) - Novartis AG:

* CURE RATE MODELING WHICH ESTIMATES FRACTION OF PATIENTS WHO MAY NOT RELAPSE WAS 54% WITH ADJUVANT TAFINLAR + MEKINIST COMPARED TO 37% WITH PLACEBO

* NOVARTIS COMBI-AD STUDY OF TAFINLAR® + MEKINIST® CONTINUES TO DEMONSTRATE RELAPSE FREE SURVIVAL BENEFIT IN PATIENTS WITH BRAF V600-MUTANT STAGE III MELANOMA Source text for Eikon: Further company coverage: (Reporting by Riham Alkousaa)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below